Sugi Predict

Sugi Predict / Compounds / SCHEMBL537189

SCHEMBL537189

SCHEMBL537189

Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n(C(=O)c2ccccc2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RNASE1 P07998 1/20 0.48
▸ TK1 P04183 3/20 0.43
▸ LMNA P02545 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TK2 O00142 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21563855 1.00 RNASE1 (0.48) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL9443821 1.00 RNASE1 (0.48) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL26233449 0.93 RNASE1 (0.42) RNASE1TK1
SCHEMBL21563929 0.92 TK1 (0.43) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL4728022 0.88 TK1 (0.53) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL9470932 0.88 LMNA (0.53) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL9470943 0.88 LMNA (0.53) RNASE1TK1LMNASMN1; SMN2TK2
SCHEMBL4730469 0.87 ALDH1A1 (0.46) RNASE1
SCHEMBL25456618 0.87 TK1 (0.38) RNASE1TK1CYP1A2
SCHEMBL779334 0.87 TK1 (0.42) RNASE1TK1LMNASMN1; SMN2TK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022160323-A1 APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES 兰州大学 2022-08-04 — — WO claimed
US-20230264164-A1 HOMOPOLYMER ENCODED NUCLEIC ACID MEMORY TRILINK BIOTECHNOLOGIES, LLC 2023-08-24 — — US disclosed
US-11612873-B2 Homopolymer encoded nucleic acid memory Molecular Assemblies, Inc. (US) 2023-03-28 — — US disclosed
WO-2022160323-A1 APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES 兰州大学 2022-08-04 — — WO disclosed
US-20190344239-A1 HOMOPOLYMER ENCODED NUCLEIC ACID MEMORY Molecular Assemblies, Inc. 2019-11-14 — — US disclosed
EP-2415777-B1 PROCESS FOR PRODUCING NUCLEOSIDE TAKEDA PHARMACEUTICAL (JP) 2015-07-29 — — EP disclosed
US-8653254-B2 Process for producing nucleoside TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-18 — — US disclosed
US-20120071646-A1 PROCESS FOR PRODUCING NUCLEOSIDE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 — — US disclosed
EP-2415777-A1 PROCESS FOR PRODUCING NUCLEOSIDE Takeda Pharmaceutical Company Limited (JP) 2012-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071646-A1 PROCESS FOR PRODUCING NUCLEOSIDE NUDT1, PNP, HPRT1 RNASE1 118/4885TK1 190/4885LMNA 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.